- Lorlatinib in the treatment of non‑small cell lung cancer2020 | Publication without faculty affiliation
- Lorlatinib in the treatment of non-small cell lung cancer2020 | First Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2021 | Publication without faculty affiliation
- Lorlatinib in a pretreated patient with ALK-positive lung adenocarcinoma2021 | Third Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2019 | Second Faculty of Medicine
- Lorlatinib2019 | Second Faculty of Medicine
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- Nemalobuněčný karcinom plic s přestavbou genu ALK a ROS1, léčený lorlatinibem2019 | Second Faculty of Medicine
- Strategie léčby ALK-pozitivního NSCLC2018 | Second Faculty of Medicine
- Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing2022 | Second Faculty of Medicine
- Současné možnosti léčby ALK-pozitivního NSCLC2021 | First Faculty of Medicine
- Komentář ke studii2023 | First Faculty of Medicine
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Current procedures and news in the treatment of lung cancer2021 | First Faculty of Medicine